Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C

References

• KanavosPDo generics offer significant savings to the UK National Health Service?Curr Med Res Opin200723110511617257472
   PubMed Web of Science ®Google Scholar
• CameronAMantel-TeeuwisseAKLeufkensHGLaingROSwitching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?Value Health201215566467322867775
   PubMed Web of Science ®Google Scholar
• GrabowskiHVernonJBrand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug ActJ Law Econ199235331250
   Web of Science ®Google Scholar
• ShihYCHanSCantorSBImpact of generic drug entry on cost-effectiveness analysisMed Decis Making2005251718015673583
   PubMed Web of Science ®Google Scholar
• GuertinJRMitchellDAliFLelorierJBias within economic evaluations - the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drugClinico Econ Outcomes Res20157497503
   Google Scholar
• McCabeCClaxtonKCulverAJThe NICE cost-effectiveness threshold: what it is and what that meansPharmacoeconomics200826973374418767894
   PubMed Web of Science ®Google Scholar
• EversonGSafety and efficacy of treatment with the interferon-free, ribavirin-free combination of sofosbuvir + GS-5816 for 12 weeks in treatment naïve patients with genotype 1–6 HCV infection49th Annual Meeting of the European Association for the Study of the LiverApril 9–13, 2014London Abstract O111
   Google Scholar
• KowdleyKVSafety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/− ribavirin in patients with chronic HCV GT1 infection: Results from the AVIATOR study48th Annual Meeting of the European Association for the Study of the LiverApril 24–28, 2013Amsterdam, The Netherlands
   Google Scholar
• LawitzESimeprevir plus sofosbuvir with/without ribavirin in HCV genotype 1 prior null-responder/treatment-naive patients (COSMOS study): primary endpoint (SVR12) results in patients with Metavir F3-4 (cohort 2)49th Annual Meeting of the European Association for the Study of the LiverApril 9–13, 2014London Abstract O165
   Google Scholar
• EversonGThulavathPLawitzEHasseneinTAll-oral combination of daclastavir, asunaprevir and BMS-791325 for HCV genotype 1 infection21st Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2014Boston Available from: http://www.natap.org/2014/CROI/croi_10.htmAccessed April 15, 2018
   Google Scholar
• SulkowskiMSGardinerDFRodriguez-TorresMRajender ReddyLDaclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infectionN Engl Med20143703211221
   PubMed Web of Science ®Google Scholar
• KnoxR$1000 pill for Hepatits C spurs debate over drug prices Available from: http://www.npr.org/blogs/health/2013/12/30/256885858/-1-000-pill-for-hepatitis-c-spurs-debate-over-drug-pricesAccessed April 15, 2018
   Google Scholar
• PatruniBNolteEHepatitis C: A Projection of the Healthcare and Economic Burden in the UKRand Health Q2013316
   Google Scholar
• Mohd HanafiahKGroegerJFlaxmanADWiersmaSTGlobal epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalenceHepatology20135741333134223172780
   PubMed Web of Science ®Google Scholar
• SimmonsBSaleemJHeathKCookeGSHillALong-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological ResponseClin Infect Dis201561573074025987643
   PubMed Web of Science ®Google Scholar
• R Core TeamR: A language and Environment for Statistical ComputingVienna, AustriaR Foundation for Statistical Computing2016 Available from: https://www.R-project.org/Accessed April 15, 2018
   Google Scholar
• Deaths Registered in England and Wales (Series DR)Office for National Statistics Available from: https://www.ons.gov.uk/people-populationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsregisteredinenglandandwalesseriesdrreferencetablesAccessed April 15, 2018
   Google Scholar
• Hepatitis C in the UK 2015 reportPublic Health England DoH2015London Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/448710/NEW_FINAL_HCV_2015_IN_THE_UK_REPORT_28072015_v2.pdfAccessed April 15, 2018
   Google Scholar
• MohsenAThe epidemiology of hepatitis C in a UK health regional population of 5.12 millionGut200148570771311302973
   PubMed Web of Science ®Google Scholar
• PetruzzielloACoppolaNDiodatoAMAge and gender distribution of hepatitis C virus genotypes in the metropolitan area of NaplesIntervirology201356320621223594735
   PubMed Web of Science ®Google Scholar
• NuZZhangPTongYAge and gender distribution of Hepatitis C virus prevalence and genotypes of individuals of physical examination in WuHan, Central ChinaSpringerplus20161351557
   Google Scholar
• McCombsJMatsudaTTonnu-MiharaIThe risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical RegistryJAMA Intern Med2014174220421224193887
   PubMed Web of Science ®Google Scholar
• Appraisal consultation document – Ledipasvir-sofosbuvir for treating chronic hepatitis CNational Institute for Health and Care Excellence2015 Available from: https://www.nice.org.uk/guidance/ta363/documents/hepatitis-c-chronic-ledipasvirsofosbuvir-id742-appraisal-consultation-document-22
   Google Scholar
• MoserSKozbialKLaferlHEfficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver diseaseEur J Gastroenterol Hepatol201830329129529120906
   PubMed Web of Science ®Google Scholar
• van de VenNFortunakJSimmonsBMinimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virusHepatology20156141174118225482139
   PubMed Web of Science ®Google Scholar
• Technology appraisal guidance – Ledipasvir-sofosbuvir for treating chronic hepatitis CNational Institute for Health and Care Excellence2015 Available from: https://www.nice.org.uk/guidance/ta363/resources/ledipasvirsofosbuvir-for-treating-chronic-hepatitis-c-pdf-82602727094725Accessed April 15, 2018
   Google Scholar
• HillAGothamDBarberMPozniakAFortunakJHepatitis C could now be cured for under US $100 per person: analysis of mass generic production of Direct Acting AntiviralsPresented at: AASLD Liver MeetingNovember 11–15, 2016Boston, MA Abstract number: 955
   Google Scholar
• HillASimmonsBGothamDFortunakJRapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis CJ Virus Erad201621283127482432
   PubMedGoogle Scholar
• HillABarberMGothamDFortunakJNathSPozniakAGeneric treatments for HIV, HBV, HCV, TB could be mass produced for <$90 per patientPresented at: 4th International HIV/Viral Hepatitis Co-Infection Meeting Abstract number 1978. Available from: https://www.researchgate.net/publication/318684251_Generic_treatments_for_HIV_HBV_HCV_TB_could_be_mass_produced_for_90_per_patientAccessed April 15, 2018
   Google Scholar
• World Health OrganizationPatent situation of key products for treatment of hepatitis C: ledipasvir2016 Available from: http://www.who.int/phi/implementation/ip_trade/ledipasvir_report.pdfAccessed April 15, 2018
   Google Scholar
• World Health OrganizationPatent situation of key products for treatment of hepatitis C: sofosbuvir2015 Available from: http://www.who.int/phi/implementation/ip_trade/sofosbuvir_report_updated.pdfAccessed April 15, 2018
   Google Scholar
• NHSHepatitis C: Essential information for professionals and guidance on testing2004 Available from: http://www.nhs.uk/hepatitisc/SiteCollectionDocuments/pdf/essential-information-for-professionals-and-guidance-on-testing.pdfAccessed April 15, 2018
   Google Scholar
• DoreGJGrebelyJNegotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030J Hepaptol2017672419420
   Web of Science ®Google Scholar
• Australian Government Department of HealthFourth national hepatitis C strategy2014 Available from: http://www.health.gov.au/internet/main/publishing.nsf/content/ohp-bbvs-hepcAccessed February 15, 2016
   Google Scholar